Alkem Laboratories Ltd's Q3FY25 Quarter Results
- 08 Feb 2025
Result Summary
- Alkem Laboratories Ltd reported a 2.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 1.5%.
- Its expenses for the quarter were down by 1.2% QoQ and up 0.9% YoY.
- The net profit decreased 8.7% QoQ and increased 6.0% YoY.
- The earnings per share (EPS) of Alkem Laboratories Ltd stood at 52.3 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 3467.27 | 3549.15 | 3417.51 | -2.3% | 1.5% |
Total Expenses | 2736.20 | 2768.89 | 2711.30 | -1.2% | 0.9% |
Profit Before Tax | 731.07 | 780.26 | 654.90 | -6.3% | 11.6% |
Tax | 90.28 | 78.30 | 50.62 | 15.3% | 78.3% |
Profit After Tax | 640.79 | 701.96 | 604.28 | -8.7% | 6.0% |
Earnings Per Share | 52.30 | 57.60 | 49.80 | -9.2% | 5.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Alkem Laboratories Ltd is a prominent pharmaceutical company engaged in the development, production, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company is headquartered in India and operates within the pharmaceutical industry, which involves a diverse range of products including generics, branded generics, over-the-counter (OTC) products, and nutraceuticals. Alkem Laboratories is recognized for its significant presence in both domestic and international markets, with a portfolio that spans a wide array of therapeutic segments. Although specific recent developments are not provided in the data, the company typically focuses on expanding its global footprint and enhancing its research and development capabilities.
Revenue
In the third quarter of fiscal year 2025 (Q3FY25), Alkem Laboratories Ltd reported a total income of ₹3,467.27 crores. This reflects a decrease of 2.3% compared to the previous quarter (Q2FY25), where the total income was ₹3,549.15 crores. On a year-over-year basis, there is an increase of 1.5% from the total income of ₹3,417.51 crores reported in the third quarter of fiscal year 2024 (Q3FY24). This marginal year-over-year growth indicates a steady performance in the company's revenue streams, despite the slight decline from the last quarter. The revenue figures highlight the company's ability to maintain its market position over the year, although there is a slight contraction when compared to the immediate preceding quarter.
Profitability
The profitability of Alkem Laboratories Ltd in Q3FY25 showed a profit before tax of ₹731.07 crores, marking a decline of 6.3% compared to the ₹780.26 crores recorded in Q2FY25. However, when compared to the same period in the previous year (Q3FY24), there is a notable increase of 11.6% from ₹654.90 crores. The tax expense for Q3FY25 was ₹90.28 crores, which is up by 15.3% from Q2FY25, and a significant 78.3% increase year-over-year from Q3FY24. The profit after tax for Q3FY25 was ₹640.79 crores, showing a decrease of 8.7% from the previous quarter but an increase of 6.0% from the same quarter last year. This pattern suggests a robust year-over-year profitability growth amidst higher tax expenses, despite a decline on a sequential quarter basis.
Operating Metrics
The company's operating metrics reveal key insights into its financial efficiency and shareholder returns. The earnings per share (EPS) for Q3FY25 was ₹52.30, down by 9.2% from ₹57.60 in Q2FY25, but up by 5.0% year-over-year from ₹49.80 in Q3FY24. This indicates a year-over-year improvement in earnings distributed per share, despite a reduction from the previous quarter. Total expenses for Q3FY25 were ₹2,736.20 crores, slightly decreasing by 1.2% from ₹2,768.89 crores in Q2FY25, and marginally increasing by 0.9% from ₹2,711.30 crores in Q3FY24. The consistent management of expenses alongside revenue growth over the year reflects on the company's operational efficiency. These operating metrics provide a comprehensive view of the company's financial health and operational performance for the period analyzed.
